During the 2016 Fall Clinical Dermatology Conference in Las Vegas from October 20th through 23rd, Biofrontera had its first official appearance at one of the largest dermatology meetings, presenting AMELUZ® (aminolevulinic acid hydrochloride) gel, 10%, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED® lamp, indicated for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp.
The nanoemulsion technology of AMELUZ® evoked a lot of interest among US dermatologists. Its unique formulation is a true innovation which has been developed in-house by Biofrontera alongside the red light BF-RhodoLED®. The combination of drug and medical device has been FDA approved in 2016.
The Fall Clinical Dermatology Conference is an annual meeting organized by the American Association of Dermatology (AAD). It is the second largest annual conference for US dermatologists and it has been a great opportunity for Biofrontera to meet with key opinion leaders, building a strong foundation of support. In addition to attending the conference, Biofrontera hosted a VIP event, to personally announce the launch of Ameluz® to the US dermatology community.
Ameluz® is commercially available in 13 countries throughout the European Union, which recently expanded the label for Ameluz® to include field-directed photodynamic therapy and the skin rejuvenation data.